본문 바로가기
KERD
논문KCI 등재

A Critical View on New and Future Antidepressants

Alessandro Serretti
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2024.05|Clinical Psychopharmacology and Neuroscience|제22권 제2호|pp. 201-210|DOI 10.9758/cpn.23.1145

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

DepressionAntidepressive agentsInvestigational drugsPrescription drugs.

초록

For the first time after many decades, many new antidepressants have been approved and many more are under various stages of development and will soon be available in the market. The new drugs present a range of new mechanisms of action with benefits in terms of speed of action, tolerability and range of treatable disorders. Neurosteroids have been recently approved and their rapid benefit may extend from postpartum depression to anxious depression and bipolar depression, dextromethorphan and bupropion combination may prove useful in major depression but also in treatment resistant depression, dextromethadone is a possible augmentation in partial antidepressant response, psychedelic drugs have the potential of long lasting benefits after a single administration, though are still experimental treatments. Botulinum has the same advantage of psychedelics of a single administration and its antidepressant effects may last for weeks or more. Further potentially interesting new antidepressant mechanisms include new drug targets, drug repurposing and genetic or epigenetic manipulations. It is therefore important that clinicians are kept up to date with new evidence so that new evidence can be rapidly translated into clinical practice.

Abstract

For the first time after many decades, many new antidepressants have been approved and many more are under various stages of development and will soon be available in the market. The new drugs present a range of new mechanisms of action with benefits in terms of speed of action, tolerability and range of treatable disorders. Neurosteroids have been recently approved and their rapid benefit may extend from postpartum depression to anxious depression and bipolar depression, dextromethorphan and bupropion combination may prove useful in major depression but also in treatment resistant depression, dextromethadone is a possible augmentation in partial antidepressant response, psychedelic drugs have the potential of long lasting benefits after a single administration, though are still experimental treatments. Botulinum has the same advantage of psychedelics of a single administration and its antidepressant effects may last for weeks or more. Further potentially interesting new antidepressant mechanisms include new drug targets, drug repurposing and genetic or epigenetic manipulations. It is therefore important that clinicians are kept up to date with new evidence so that new evidence can be rapidly translated into clinical practice.

참고문헌 (103)

  1. GBD 2019 Mental Disorders Collaborators, "Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019 : a systematic analysis for the Global Burden of Disease Study 2019", Lancet Psychiatry, 9, pp.137~150 (2022)
  2. Serretti A, "The present and future of precision medicine in psychiatry : focus on clinical psychopharmacology of antidepressants", Clin Psychopharmacol Neurosci, 16, pp.1~6 (2018)
  3. van Broekhoven F, "Neurosteroids in depression : a review", Psychopharmacology(Berl), 165, pp.97~110 (2003)
  4. Uzunova V, "Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action", Psychopharmacology(Berl), 186, pp.351~361 (2006)
  5. Schüle C, "Neuroactive steroids in affective disorders : target for novel antidepressant or anxiolytic drugs?", Neuroscience, 191, pp.55~77 (2011)
  6. Brown ES, "A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression", Neuropsychopharmacology, 39, pp.2867~2873 (2014)
  7. Kanes S, "Brexanolone(SAGE-547 injection)in post-partum depression : a randomised controlled trial", Lancet, 390, pp.480~489 (2017)
  8. Gunduz-Bruce H, "Trial of SAGE-217 in patients with major depressive disorder", N Engl J Med, 381, pp.903~911 (2019)
  9. Clayton AH, "Zuranolone for the treatment of adults with major depressive disorder : a randomized, placebo-controlled phase 3 trial", Am J Psychiatry, 180, pp.676~684 (2023)
  10. Walkery A, "Review of allopregnanolone agonist therapy for the treatment of depressive disorders", Drug Des Devel Ther, 15, pp.3017~3026 (2021)
  11. Meshkat S, "Clinical efficacy and safety of Zuranolone(SAGE-217)in individuals with major depressive disorder", J Affect Disord, 340, pp.893~898 (2023)
  12. Deligiannidis KM, "Effect of zuranolone vs placebo in postpartum depression : a randomized clinical trial", JAMA Psychiatry, 78, pp.951~959 (2021)
  13. Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)2018 guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
  14. Taylor CP, "Pharmacology of dextromethorphan : relevance to dextromethorphan", quinidine(NuedextaⓇ)clinical use, 2016, pp.164, 170~182
  15. Zimmerman M, "Why isn’t bupropion the most frequently prescribed antidepressant?", J Clin Psychiatry, 66, pp.603~610 (2005)
  16. Güzey C, "Change from the CYP2D6extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion", Ther Drug Monit, 24, pp.436~437 (2002)
  17. Kotlyar M, "Inhibition of CYP2D6 activity by bupropion", J Clin Psychopharmacol, 25, pp.226~229 (2005)
  18. Stahl SM, "Dextromethorphan", bupropion : a novel oral NMDA(N-methyl-d-aspartate)receptor antagonist with multimodal activity-Addendum, 2020, pp.25, 803~
  19. Tabuteau H, "Effect of AXS-05(dextromethorphan-bupropion)in major depressive disorder : a randomized double-blind controlled trial", Am J Psychiatry, 179, pp.490~499 (2022)
  20. Iosifescu DV, "Efficacy and safety of AXS-05(dextromethorphan-bupropion)in patients with major depressive disorder : a Phase 3 randomized clinical trial(GEMINI)", J Clin Psychiatry, 83, pp.21~ (2022)
  21. Parincu Z, "Combinations of dextromethorphan for the treatment of mood disorders-a review of the evidence", Expert Rev Neurother, 23, pp.205~212 (2023)
  22. Bernstein G, "Characterization of the safety and pharmacokinetic profile of D-methadone, a novel N-methyl-D-aspartate receptor antagonist in healthy, opioid-naive subjects : results of two phase 1 studies", J Clin Psychopharmacol, 39, pp.226~237 (2019)
  23. Gorman AL, "The d-and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate(NMDA)receptor in rat forebrain and spinal cord", Neurosci Lett, 223, pp.5~8 (1997)
  24. Nemeroff CB, "Back to the future : Esmethadone, the(maybe)nonopiate opiate, and depression", Am J Psychiatry, 179, pp.83~84 (2022)
  25. Rasch M, "Dextromethadone and its antitussive effect", Nord Med, 57, pp.629~631 (1957)
  26. Judson BA, "Side effects of levomethadone and racemic methadone in a maintenance program", Clin Pharmacol Ther, 20, pp.445~449 (1976)
  27. Hanania T, "The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats", Exp Clin Psychopharmacol, 28, pp.196~201 (2020)
  28. Fogaça MV, "N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects", Neuropsychopharmacology, 44, pp.2230~2238 (2019)
  29. Henter ID, "Novel glutamatergic modulators for the treatment of mood disorders : current status", CNS Drugs, 35, pp.527~543 (2021)
  30. Fava M, "REL-1017(Esmethadone)as adjunctive treatment in patients with major depressive disorder : a phase 2a randomized double-blind trial", Am J Psychiatry, 179, pp.122~131 (2022)
  31. Guidetti C, "REL-1017(Esmethadone)may rapidly reduce dissociative symptoms in adults with major depressive disorder unresponsive to standard antidepressants : a report of 2 cases", J Clin Psychopharmacol, 42, pp.503~506 (2022)
  32. Guidetti C, "Subanalysis of subjective cognitive measures from a phase 2, double-blind, randomized trial of REL-1017 in patients with major depressive disorder", Prim Care Companion CNS Disord, 25, pp.22~ (2023)
  33. Fava M, "Esmethadone-HCl(REL-1017) : a promising rapid antidepressant", Eur Arch Psychiatry Clin Neurosci, 273, pp.1463~1476 (2023)
  34. Zarate CA Jr, "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression", Arch Gen Psychiatry, 63, pp.856~864 (2006)
  35. Tham JCW, "Repeated subcutaneous racemic ketamine in treatment-resistant depression : case series", Int Clin Psychopharmacol, 37, pp.206~214 (2022)
  36. Moccia L, "Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression : a single-case report", Int Clin Psychopharmacol, 37, pp.21~24 (2022)
  37. Jelen LA, "Ketamine for depression", Int Rev Psychiatry, 33, pp.207~228 (2021)
  38. Smith-Apeldoorn SY, "Maintenance ketamine treatment for depression : a systematic review of efficacy, safety, and tolerability", Lancet Psychiatry, 9, pp.907~921 (2022)
  39. Farnsworth NR, "Hallucinogenic plants. Various chemical substances are known to be the active hallucinogenic principles in many plants", Science, 162, pp.1086~1092 (1968)
  40. Young SN, "Single treatments that have lasting effects : some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin", J Psychiatry Neurosci, 38, pp.78~83 (2013)
  41. Baumeister D, "Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles", Ther Adv Psychopharmacol, 4, pp.156~169 (2014)
  42. Carhart-Harris R, "Trial of psilocybin versus escitalopram for depression", N Engl J Med, 384, pp.1402~1411 (2021)
  43. Goldberg SB, "The experimental effects of psilocybin on symptoms of anxiety and depression : a meta-analysis", Psychiatry Res, 284, pp.112749~ (2020)
  44. Perez N, "Psilocybin-assisted therapy for depression : a systematic review and dose-response meta-analysis of human studies", Eur Neuropsychopharmacol, 76, pp.61~76 (2023)
  45. Daws RE, "Increased global integration in the brain after psilocybin therapy for depression", Nat Med, 28, pp.844~851 (2022)
  46. Ehrmann K, "Psilocybin for the treatment of obsessive-compulsive disorders", Curr Top Behav Neurosci, 56, pp.247~259 (2022)
  47. Moreno FA, "Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder", J Clin Psychiatry, 67, pp.1735~1740 (2006)
  48. Schneier FR, "Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder", J Psychiatr Res, 161, pp.364~370 (2023)
  49. Bogenschutz MP, "Psilocybin-assisted treatment for alcohol dependence : a proof-of-concept study", J Psychopharmacol, 29, pp.289~299 (2015)
  50. Johnson MW, "Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction", J Psychopharmacol, 28, pp.983~992 (2014)
  51. de Veen BT, "Psilocybin for treating substance use disorders?", Expert Rev Neurother, 17, pp.203~212 (2017)
  52. Serretti A, "Anhedonia and depressive disorders", Clin Psychopharmacol Neurosci, 21, pp.401~409 (2023)
  53. Doss MK, "Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder", Transl Psychiatry, 11, pp.574~ (2021)
  54. Becker AM, "Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects", Clin Pharmacol Ther, 111, pp.886~895 (2022)
  55. Erritzoe D, "Effects of psilocybin therapy on personality structure", Acta Psychiatr Scand, 138, pp.368~378 (2018)
  56. MacLean KA, "Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness", J Psychopharmacol, 25, pp.1453~1461 (2011)
  57. Lyons T, "Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression", J Psychopharmacol, 32, pp.811~819 (2018)
  58. Weiss B, "Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression", Psychol Med, pp.1~15 (2023)
  59. Husain MI, "Psilocybin for treatment-resistant depression without psychedelic effects : study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial", BJPsych Open, 9, pp.e134~ (2023)
  60. Rosenblat JD, "The Canadian Network for Mood and Anxiety Treatments(CANMAT)task force report : serotonergic psychedelic treatments for major depressive disorder", Can J Psychiatry, 68, pp.5~21 (2023)
  61. Santos RG, "Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members", J Ethnopharmacol, 112, pp.507~513 (2007)
  62. Uthaug MV, "A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats", Psychopharmacology(Berl), 238, pp.1899~1910 (2021)
  63. Sanches RF, "Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression : a SPECT study", J Clin Psychopharmacol, 36, pp.77~81 (2016)
  64. Palhano-Fontes F, "Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression : a randomized placebo-controlled trial", Psychol Med, 49, pp.655~663 (2019)
  65. González D, "Therapeutic potential of ayahuasca in grief : a prospective, observational study", Psychopharmacology(Berl), 237, pp.1171~1182 (2020)
  66. Galvão-Coelho NL, "Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca", J Psychopharmacol, 34, pp.1125~1133 (2020)
  67. Zeifman RJ, "Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder : results from an open-label trial", Psychopharmacology(Berl), 238, pp.453~459 (2021)
  68. Valentini E, "Suicidality in a psychiatric inpatient unit : a 2-year retrospective study in Umbria, central Italy", Int Clin Psychopharmacol, 38, pp.154~159 (2023)
  69. Olgiati P, "Persistence of suicidal ideation within acute phase treatment of major depressive disorder : analysis of clinical predictors", Int Clin Psychopharmacol, 37, pp.193~200 (2022)
  70. Miller AH, "Psychedelics and ketamine are a symptom of psychiatry’s woes, not a cure", Mol Psychiatry, 28, pp.3167~3168 (2023)
  71. Tariq R, "Using Psychedelics in clinical practice : comparing therapeutic uses and potential harms", Curr Rev Clin Exp Pharmacol, 18, pp.94~109 (2023)
  72. Benedetti F, "Antidepressant psychopharmacology : is inflammation a future target?", Int Clin Psychopharmacol, 37, pp.79~81 (2022)
  73. Sun Y, "The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman’s disease", Brain Behav Immun, 66, pp.156~164 (2017)
  74. Zhou AJ, "Sirukumab : a potential treatment for mood disorders?", Adv Ther, 34, pp.78~90 (2017)
  75. Griffiths CEM, "Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis : an integrated analysis of three phase 3 clinical studies", Psychother Psychosom, 86, pp.260~267 (2017)
  76. Serretti A, "Clinical utility of fluid biomarker in depressive disorder", Clin Psychopharmacol Neurosci, 20, pp.585~591 (2022)
  78. Luvisetto S, "Botulinum neurotoxins in central nervous system : an overview from animal models to human therapy", Toxins(Basel), 13, pp.751~ (2021)
  79. Li Y, "Botulinum toxin A(BoNT", A)for the treatment of depression : a randomized, double-blind, placebo, controlled trial in China, 2022, pp.318, 48~53
  80. Wollmer MA, "Facing depression with botulinum toxin : a randomized controlled trial", J Psychiatr Res, 46, pp.574~581 (2012)
  81. Magid M, "Treatment of major depressive disorder using botulinum toxin A : a 24-week randomized, doubleblind, placebo-controlled study", J Clin Psychiatry, 75, pp.837~844 (2014)
  82. Brin MF, "OnabotulinumtoxinA for the treatment of major depressive disorder : a phase 2 randomized, double-blind, placebocontrolled trial in adult females", Int Clin Psychopharmacol, 35, pp.19~28 (2020)
  83. Zhang Q, "The safety and efficacy of botulinum toxin A on the treatment of depression", Brain Behav, 11, pp.e2333~ (2021)
  84. Wollmer MA, "Treatment of depression with botulinum toxin", Toxins(Basel), 14, pp.383~ (2022)
  85. Wollmer MA, "The use of botulinum toxin for treatment of depression", Handb Exp Pharmacol, 263, pp.265~278 (2021)
  86. Lehnert F, "Botulinum toxin therapy for psychiatric disorders in clinical practice : a retrospective case study", Toxins(Basel), 15, pp.385~ (2023)
  87. Liu L, "Gut microbiota and its metabolites in depression : from pathogenesis to treatment", EBioMedicine, 90, pp.104527~ (2023)
  88. Musazadeh V, "Probiotics as an effective therapeutic approach in alleviating depression symptoms : an umbrella meta-analysis", Crit Rev Food Sci Nutr, 63, pp.8292~8300 (2023)
  89. Musazadeh V, "Anti-obesity properties of probiotics; a considerable medical nutrition intervention : findings from an umbrella meta-analysis", Eur J Pharmacol, 928, pp.175069~ (2022)
  90. Zarezadeh M, "Effects of probiotics supplementation on blood pressure : an umbrella meta-analysis of randomized controlled trials", Nutr Metab Cardiovasc Dis, 33, pp.275~286 (2023)
  91. Xu D, "Role of probiotics", synbiotic supplementation in glycemic control : a critical umbrella review of meta-analyses of randomized controlled trials, 2022, 1~19
  92. Scala M, "Clinical specificity profile for novel rapid acting antidepressant drugs", Int Clin Psychopharmacol, 38, pp.297~328 (2023)
  93. Schatzberg AF, "The why, when, where, how, and so what of so-called rapidly acting antidepressants", Neuropsychopharmacology, 49, pp.189~196 (2024)
  94. Kolahdooz G, "The effect of crocin versus sertraline in treatment of mild to moderate postpartum depression : a double-blind, randomized clinical trial", Int Clin Psychopharmacol, 38, pp.9~15 (2023)
  95. Elnazer HY, "Effects of celecoxib augmentation of antidepressant or anxiolytic treatment on affective symptoms and inflammatory markers in patients with anxiety disorders : exploratory study", Int Clin Psychopharmacol, 36, pp.126~132 (2021)
  96. Farajollahi-Moghadam M, "Efficacy and safety of pentoxifylline combination therapy in major depressive disorder : a randomized, double-blind, placebo-controlled clinical trial", Int Clin Psychopharmacol, 36, pp.140~146 (2021)
  97. Hori H, "Doxazosin improved COVID-19 associated nightmare in a patient with major depressive disorder : a case report with a positive rechallenge", Int Clin Psychopharmacol, 36, pp.221~223 (2021)
  98. Serretti A, "Psychopharmacology : past, present and future", Int Clin Psychopharmacol, 37, pp.82~83 (2022)
  99. Serretti A, "Advances in the treatment of depression", Int Clin Psychopharmacol, 37, pp.183~184 (2022)
  100. Miller AH, "Burning down the house : reinventing drug discovery in psychiatry for the development of targeted therapies", Mol Psychiatry, 28, pp.68~75 (2023)
  101. Sun N, "Design of fast-onset antidepressant by dissociating SERT from nNOS in the DRN", Science, 378, pp.390~398 (2022)
  102. Singh D, "A complete sojourn of gene therapy along with its targeting approaches for the treatment of the major depressive disorder", Curr Gene Ther, 23, pp.276~290 (2023)
  103. Grinstein JD, "Alto neuroscience announces positive phase II results supporting precision psychiatry platform", GEN Edge, 5, pp.36~38 (2023)

관련 논문AI추천

Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives김용구, 신민철대한신경정신의학회 · PSYCHIATRY INVESTIGATION2020 · 제17권 제3호Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical PracticeAlessandro Serretti대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2025 · 제23권 제4호Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive DisorderAndrew Muzyk, Brian McCarthy, Charlotte Wilmouth, Colin M. Smith, Hannah Bunn, Morgan Santalucia대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2023 · 제21권 제4호항우울제로 새롭게 등장한 ‘남용 물질’ - 약리학적 기전, 항우울 효과, 오남용 가능성에 대한 고찰강웅구, 박선영, 안유석대한신경정신의학회 · 신경정신의학2022 · 제61권 제4호미래의 항우울제이민수, 사공정규대한생물치료정신의학회 · 생물치료정신의학2011 · 제17권 제2호The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of AntidepressantsAlessandro Serretti대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2018 · 제16권 제1호

이 간행물의 다른 논문 (19건)

Bipolar Disorder, Circadian Rhythm and Clock GenesYoung-Chan Kim, Junsoo Chung, 정종현pp. 211-221Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical TrialsHyun Kook Lim, 배치운, 김성환, Young Sup Woo, Sheng-Min Wang, Won-Myong Bahk, Won-Seok Choipp. 222-231Augmentation Strategies for Partial or Non-responders to Clozapine in Patients with Schizophrenia: A Bayesian Network Meta-analysis of Randomized Controlled TrialsAnand Srinivasan, Archana Mishra, Rituparna Maiti, Biswa Ranjan Mishrapp. 232-252Effect of Frailty on Depression among Patients with Late-life Depression: A Test of Anger, Anxiety, and Resilience as MediatorsHyun-Ghang Jeong, 이문수, 배치운, Changsu Han, Junhyung Kim, Ashwin A. Patkar, Cheolmin Shin, Sang Won Jeonpp. 253-262The Dropout Rates and Associated Factors in Patients with Mood Disorders in Long-term Naturalistic TreatmentHee Jeong Jeong, Je Min Park, Wooyoung Jung, Byung Dae Lee, Young Min Lee, Hwagyu Suh, Hyun Ju Lim, Eunsoo Moon, Kyungwon Kimpp. 263-275
원문 보기